Matching geography
Reports matching your search in:
 
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 
Region: All Regions > Europe
Category: All Categories > Life Sciences > Pharmaceuticals > Country Overviews
(290 reports matching your criteria)
1  2    4    6  7  8  9  10  
Poland Pharmaceuticals and Healthcare Report Q2 2014
2/12/2014 | published by: Business Monitor International
... pressures in 2014,while multinational drugmakers will welcome the decision to improve access to innovative therapies forcancer patients. With among the lowest drug prices in Europe, we expect patented drugs to outperform overthe short-term as cost ...  |  read more...
USD 1,295
Austria Pharmaceuticals and Healthcare Report Q2 2014
2/12/2014 | published by: Business Monitor International
... climate in Austria's primarytrading partner, Germany, has improved outlook for the industry, growth will remain subdued in themedium term and strengthening EUR-USD will affect returns for overseas investors. The Austrianpharmaceutical market is relatively small in ...  |  read more...
USD 1,295
Pharmaceutical And Healthcare Market In Poland 2013
6/1/2013 | published by: PMR
... pharmaceutical and healthcare markets. The experienced analysts at PMR have kept close watch on these changes, observing events and collecting data that documents variations in sales values of various medications, the value of the hospital ...  |  read more...
USD 2,660
Pharmaceuticals in Spain: ISIC 2423
4/18/2013 | published by: Euromonitor International
... at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing ...  |  read more...
USD 600
Serbia Pharmaceuticals and Healthcare Report Q2 2013
4/17/2013 | published by: Business Monitor International
... consumption is also expected to rise. However, financial inefficiencies within the healthinsurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet itsobligations on time, leaving patients to pay for formerly ...  |  read more...
USD 1,295
Bulgaria Pharmaceuticals and Healthcare Report Q2 2013
4/10/2013 | published by: Business Monitor International
... parties to force thegovernment to mandate currently voluntary price discounts through legislation. The potentialintroduction of additional restrictive policies – on top of the implemented mark-up ceilings forwholesalers and manufacturers and the expansion of countries in ...  |  read more...
USD 1,295
Belgium Pharmaceuticals and Healthcare Report Q2 2013
4/10/2013 | published by: Business Monitor International
... focus on cost-containment in the sphere of public spending. Nevertheless, patented medicines will continue to represent the bulk of prescription spending in thecountry, thus continuing to create commercial opportunities for the manufacturers of novel products. ...  |  read more...
USD 1,295
Pharmaceuticals in Germany: ISIC 2423
2/6/2013 | published by: Euromonitor International
... the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new ...  |  read more...
USD 600
Greece Pharmaceuticals and Healthcare Report Q1 2013
1/30/2013 | published by: Business Monitor International
... shifted some of the burden of healthcarespending onto its citizens, requiring co-payments for expensive drugs. While we continue to hold to our view that Germany and the rest of the EU may reduce the focus ...  |  read more...
USD 1,295
Romania Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... are a small improvement, though definitely not what producerswould have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness ofpayments for reimbursed medicines, which has been a major difficulty ...  |  read more...
USD 1,295
Portugal Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...  |  read more...
USD 1,295
Hungary Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... margins and introduced insecurityto an already difficult economic environment, and we continue to expect a contraction in the size of theHungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have tobecome even more ...  |  read more...
USD 1,295
Slovakia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... this is realised. We do not expect either of the two private insurers - Dôvera or DutchownedUnion - will surrender their businesses without a fight, with Union in particular well-placedto oppose the move, potentially invoking ...  |  read more...
USD 1,295
Pharmaceuticals in United Kingdom: ISIC 2423
1/15/2013 | published by: Euromonitor International
... the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new ...  |  read more...
USD 600
Ukraine Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... represent a very large business risk for internationaldrugmakers operating in the country. While Ukraine remains one of Central and Eastern Europe (CEE)'smore promising pharmaceutical markets given its favourable demographics and disease profile, itschronic lack of ...  |  read more...
USD 1,295
Poland Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... has shifted towards the Polishconsumer, as the harsher reimbursement regime has caused private contributions to prescriptionpayments rise. We forecast a return to growth in 2013, driven by private consumption as the Polishgovernment entrenches cuts to ...  |  read more...
USD 1,295
Croatia Pharmaceuticals and Healthcare Report Q1 2013
12/26/2012 | published by: Business Monitor International
... from the EU. The implementation of a clawbacktax at the start of the year will increase pricing pressures. VAT rises and inflation suggest growth seen in2012 will not be due to increased drug consumption. We ...  |  read more...
USD 1,175
Italy Pharmaceuticals and Healthcare Report Q1 2013
12/26/2012 | published by: Business Monitor International
... theyear. BMI notes that this does not bode well for drugmakers selling their products in Italy as the successof the implemented policies may encourage the enforcement of further cost-containment measures,which, together with the ongoing public ...  |  read more...
USD 1,175
Pharmaceuticals in France: ISIC 2423
12/18/2012 | published by: Euromonitor International
... the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new ...  |  read more...
USD 600
Intellinews - Polish Pharmaceutical Sector Report - October 2012
11/2/2012 | published by: Intellinews
... comments. This sector report is ideal to keep you abreast on recent company and industry news. Written by local professionals, it is a unique market and business intelligence analysis, tailored to save time by providing ...  |  read more...
USD 240
Czech Republic Pharmaceuticals and Healthcare Report Q4 2012
10/26/2012 | published by: Business Monitor International
... with measures designedto tighten public expenditure across the board, while the challenging economic outlook willnegatively affect the availability of private funding for medical products and services. Despite mediumtermconcerns, after 2012 we expect more normal growth ...  |  read more...
USD 1,175
Belarus Pharmaceuticals and Healthcare Report Q4 2012
10/26/2012 | published by: Business Monitor International
... Eastern European markets, the economy remains vulnerable to political mismanagementand the business environment is undesirable. However, we are expecting stronger growth in 2013, withthe pharmaceutical market expected to post its first year of dollar growth ...  |  read more...
USD 1,175
Greece Pharmaceuticals and Healthcare Report Q4 2012
10/26/2012 | published by: Business Monitor International
... –and could still be – disastrous for drugmakers operating in the market. But even Greece staying in themonetary union means the government must continue with its austerity programme. While we continue tohold to our view ...  |  read more...
USD 1,175
Spain Pharmaceuticals and Healthcare Report Q4 2012
10/26/2012 | published by: Business Monitor International
... theyear. BMI notes that this does not bode well for drugmakers selling their products in Spain as the successof the implemented policies may encourage the enforcement of further cost-containment measures, which,together with the ongoing public ...  |  read more...
USD 1,175
Estonia Pharmaceuticals and Healthcare Report Q4 2012
10/10/2012 | published by: Business Monitor International
... economic conditions, patent expirations and government encouragementof the consumption of cheaper generic medicine. We expect imports to remain of crucial importance tomarket supply, with Estonia lacking a major domestic drug producer and with local research ...  |  read more...
USD 1,175
1  2    4    6  7  8  9  10